(return to
Forced Drugging)
Neuroleptics and Brain Damage: An Annotated Bibliography
(last updated Sept. 28, 1999)
Recent evidence of brain changes in humans associated with
neuroleptic drugs:
Gur, R.E., Maany, V., Mozley, P.D., Swanson, C., Bilker, W.,
& Gur, R.C. (1998). Subcortical MRI volumes in neuroleptic-naive
and treated patients with schizophrenia. American Journal of
Psychiatry, 155 (12), 1711-1717. Using MRI imaging, this study
monitored changes in the size of the basal ganglia and thalamic
regions of the brain as patients were treated with neuroleptic
drugs. Treatment by neuroleptics increased the area of both regions.
For typical neuroleptics, a higher dose was associated with a size
increase in multiple areas, while atypcal neuroleptics increased the
volume only of the thalamic portion. Furthermore, these researchers
reported that increased size of these portions of the brain is
associated with greater severity of symptoms. In other words, the
patient’s brains were being changed in ways that would likely make
it more difficult for them to ever withdraw from neuroleptic
Chakos, M.H., Lieberman, J.A., Bilder, R.M., Borenstein, M.,
Lerner, G., Bogerts, B., Wu, H., Kinon, B., & Ashtari, M.
(1994). Increase in caudate nuclei volumes of first-episode
schizophrenic patients taking antipsychotic drugs. American Journal
of Psychiatry 151 (10) 1430- 1436. Based on MRI measurements of
patients who initially had under 12 weeks of lifetime exposure to
neuroleptics, and comparison with data after 18 months of treatment,
the authors concluded that "caudate enlargement occurs early in the
course of treatment in young first-episode schizophrenic patients.
This may be a result of an interaction between neuroleptic treatment
and the plasticity of dopaminergic neuronal systems in young
patients." It was known prior to this study that chronically treated
patients had increased volumes in this portion of their brains, but
it had been thought this was due to the disease and not the
treatment...drugs.
1998. Neuroleptics in progressive structural brain abnormalities
in psychiatric illness.(Research Letters). The Lancet, 352 (9130)
784. This was a longitudinal study of patients, some schizophrenic,
some not, from the beginning of their treatment with neuroleptics
until 5 years later. Before and after scans of the brain were done
using computed tomography (CT). The finding was that diagnosis had
no significant impact on the development of frontal atrophy, but
that “the estimated risk of atrophy increases by 6.4% for each
additional 10 g neuroleptic drug.”
Gur, R.E, Cowell, P., Turetsky, B.I., Gallacher, F., Cannon, ?,
Bilker, W., & Gur, R.C. (1998) A follow-up magnetic resonance
imaging study of schizophrenia. Archives of General Psychiatry, 55
145-152. This study looked at changes in the frontal and temporal
lobes of the brains of schizophrenics over a period of about 31
months. They found that for first episode patients, “higher
medication dose was associated with greater reduction in frontal and
temporal volume r = -0.75 and -0.66 respectively; P<.001).”
Volume reduction was associated with decline in some neurobehavioral
functions.
Evidence that Tardive Dyskinesia [TD - a well-established form of
neuroleptic-induced brain damage that can result in permanent
twitching of face and limbs] involves brain changes that impact
cognitive functioning:
Paulsen, J. S., Heaton, R.K., & Jeste, D.V. (1994).
Neuropsychological impairment in tardive dyskinesia.
Neuropsychology,8 (2), 227-241. The authors reviewed 31 published
studies of neuropsychological testing comparing schizophrenics with
and without TD. 24 of these studies, or 77%, found TD patients did
worse on such tests. In an attempt to improve on past studies, the
authors did their own study which matched patients with and without
TD on a variety of measures, including duration and severity of
illness. Those with TD demonstrated greater neuropsychological
impairment, and those with more severe TD manifested greater
neuropsychological impairment. The authors go on to discuss brain
changes which may be associated with both TD and neuropsychological
impairment, and concludes that “it is likely that TD involves an
alteration of brain function that affects both motor and cognitive
control.”
Waddington, J.L., & Youssef, H.A. (1996). Cognitive
dysfunction in chronic schizophrenia followed prospectively over 10
years and its longitudinal relationship to the emergence of tardive
dyskinesia. Psychological Medicine, 26 681-688. Often the
relationship between cognitive dysfunction and TD has been explained
by suggesting that those with underlying cognitive dysfunctions are
more prone to TD. This study sharply contradicts that explanation.
The authors followed the cognitive functioning of a group of chronic
schizophrenic patients over 10 years. Most were stable in regards to
cognitive functioning: the exceptions were the individuals who
developed TD during the course of the study. The authors write that
“Those patients demonstrating prospectively the emergence of
orofacial dyskinesia showed a marked deterioration in their
cognitive function over the same time-frame withing which their
movement disorder emerged, but this decline did not progress
thereafter.” The authors conclude that the cognitive changes are
related to the patho-physiological process which also results in TD.
Sachdev, P., Hume, F., Toohey, P., & Doutney, C. (1996).
Negative symptoms, cognitive dysfunction, tardive akathisia and
tardive dyskinesia. Acta Psychiatrica Scandinavica, 93 (6), 451-459.
The authors, in their literature review, point out that while there
are some studies that do not find a relationship between TD and
cognitive deficits, there are many that do show a positive
relationship between TD and cognitive deficits and none that show
the opposite relationship. In the current study, TD was shown to be
related to cognitive deficits, while tardive akathisia was shown to
be even more strongly related to cognitive deficits. While the
authors do not see this as proving that neuroleptics cause cognitive
deficits, they recommend considering the possibility, and they
compare TD and TA with other movement disorders such as Parkinson’s
disease and Huntington’s disease, in which neuropsychological
deficits and even subcortical dementia are known to occur.
Wade, J.B., Lehmann, L., Hart, R., Linden, D., Novak, T., &
Hamer, R. (1989). Cognitive changes associated with tardive
dyskinesia. Neuropsychiatry, Neuropsychology, and Behavioral
Neurology, 1 (3), 217-227. “The results of multip regression
analysis revealed a modest linear relationship between TD and
cognition (p<.04) after controlling for the effects of years of
illness, duration of hospitalization, motor speed, severity of
illness, and medication.” The authors conclude that “our findings
suggest that TD may represent both a motor and dementing disorder
regardless of major psychiatric diagnosis.”
Famuyiwa, O.O., Eccleston, D., Donaldson, A.A., & Garside,
R.F. (1979). Tardive dyskinesia and dementia. British Journal of
Psychiatriy, 135 500-504. Schizophrenics both with and without
tardive dyskinesia were compared with both EMI scans and
psychological tests of intellectual function. Those with TD did
worse on the tests, and it was suggested that the higher incidence
of pathology in that group might be related to chronic neuroleptic
toxicity.
Edwards, H. (1970). The significance of brain damage in
persistant oral dyskinesia. British Journal of Psychiatry, 116,
271-275. The author sought to discover whether brain damage could be
an important contributory cause of TD. To examine that possibility,
he compared two samples matched for phenothiazine intake and age,
one sample with TD, the other without. Both groups were checked for
brain damage and dementia. 28 out of 34 in the group with TD, versus
14 out of 34 controls, showed at least some brain damage. Edwards
mostly focused on brain damage putting patients at risk for TD, but
he also raised the possibility that the drugs themselves cause
permanent neurological damage.
Wade, J.B., Taylor, M.A., Kasprisin, A., Rosenberg, S., &
Fiducia, D. (1987). Tardive dyskinesia and cognitive imparment.
Biological Psychiatry, 22 393-395. Because not all studies have
found a relationship between tardive dyskinesia and cognitive
functioning, the authors conducted a study using tasks known to find
cognitive impairment in Parkinson’s and Huntington’s diseases. These
tasks were chosen because the authors believed these diseases might
provide a neuropsychological, as well as a biochemical, model for
TD. The authors found a modest but significant linear relationship
between TD and reduced cognitive functioning, where those with the
most severe forms of the disorder were most impaired cognitively.
Neuroleptics increase cognitive decline in elderly people with
dementia:
McShane, R., Keene, J., Gedling, K., Fairburn, C., Jacoby, R.,
& Hope, T. (1997). Do neuroleptic drugs hasten cognitive decline
in dementia? Prospective study with necropsy follow up. British
Medical Journal, 314 (7076), 266-271. This study looked at the
impact of long term use of neuroleptics on the cognitive function of
elderly people with dementia. It found that cognitive function
declined twice as fast in those taking neuroleptics as in those not
on neuroleptics. Brain differences were not found at autopsy, which
means either that the cognitive decline was functional only, or that
the brain differences escaped detection by the methods these
researchers used.
A sampling of some of the animal studies showing brain changes
afer neuroleptics:
Benes, F.M., Paskevich, P.A., Davidson, J., & Domesick, V.B.
(1985) The effects of haloperidol on synaptic patterns in the rat
striatum. Brain Research, 329, 265-274. This study finds changes in
cell size and in number of vesicles in rats in a particular part of
their brain. The authors cite other studies which have also found
changes in rat brains caused by neuroleptics. In their conclusion
the authors state that “The results of this study provide further
evidence that haloperidol can induce synaptic alterations in the rat
central nervous system, an effect which we first noted in the rat
substantia nigra.”
Muller, P. & Seeman, P. (1977). Brain Neurotransmitter
receptors after long-term haloperidol: dopamine, acetylcholine,
serotonin, -Noradrenergic and naloxone receptors. Life Sciences 21,
1751-1758. This study looked at the effect of chronic haloperidol on
a variety on neurotransmitters in rats. The authors concluded that
“these results indicate that long-term haloperidol treatment
produces rather selective increases in dopamine/neuroleptic
receptors, without much change in 4 other types of receptors.” The
dopamine receptor changes were very significant though, ranging from
34 to 45%.
Burt, D.R., Creese, I., & Snyder, S.H. (1977).
Antischizophrenic drugs: Chronic treatment elevates dopamine
receptor binding in brain. Science, 196, 326-328. Another study
looking at changes in dopamine receptors. “Chronic treatment of rats
with the neuroleptic drugs haloperidol, fluphenazine , and reserpine
elicits a 20 to 25 percent increase in striatal dopamine receptor
binding assayed with Haloperidol.”
Jeste, D.V., Lohr, J.B., & Manley, M. (1992). Study of
neuropathologic changes in the striatum following 4, 8 and 12 months
of treatment with fluphenazine in rats. Psychopharmacology, 106,
154-160. In the literature review of research over 3 decades, most
studies listed found brain changes. The current study also found
brain changes: a lower density of large neurons in the striatum of
middle aged rats. Older rats did not show significant differences,
which the authors felt was because the neuroleptics were
accelerating the loss of large neurons which naturally die later as
a result of aging.
Nielsen, E.B., & Lyon, M. (1978). Evidence for cell loss in
corpus striatum after long-term treatment with a neuroleptic drug
(flupenthixol) in rats. Psychopharmacology, 59 85-89. The authors
found a 10% cell loss in one region of the rat’s brains, which they
concluded “further suggest that persistent irreversible anatomical
changes can follow long-term neuroleptic treatment.”
Pakkenberg, H., Fog, R., & Nilakantan, B. (1973) The long
term effect of perphenazine enanthate on the rat brain. Some
metabolic and anatomical observations. This study found a
significant decrease in the number of nerve cells in the basal
ganglia of rats under long-term treatment.
Chakos, M.H., Shirakawa, O., Lieberman, J., Lee, H., Bilder, R.,
& Tamminga, C.A. (1998). Striatal enlargement in rats
chronically treated with neuroleptic. Biological Psychiatry, 44 (8),
675-684. The authors sought to find out whether the striatal
enlargement found in humans treated with neuroleptics also occurred
in rats. This was seen as important, since there remained the
possibility that the changes in striatal volume seen to occur with
neuroleptic treatment might be part of some disease process in human
subjects with schizophrenia. Also, there had been some speculation
that the apparent growth in the striatum of humans seen with MRI
scans really were just changes in blood flow or metabolism. This
study found, however, that rats experienced a similar growth in
their striatum, as measured at autopsy. It also found that rats with
movement disorders experienced greater growth in their striatum than
did rats without such disorders. The authors, in their conclusion,
state that “It is possible that neuroleptic-induced striatal volume
changes play a role in the development of subtle cognitive
impairment as well as the development of a movement disorder in
vulnerable patients. An association between striatal enlargement and
cognitive impairment has, in fact, been reported by Hokama et al
(1995).”